Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04870606 · ClinicalTrials.gov registry record · Phase 3
Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness
A Phase 3 study, sponsored by Suzhou Kintor Pharmaceutical Inc,.
- Completed
- Registry status
- Phase 3
- Development phase
- 733
- Enrollment target
NCT04870606: Completed Phase 3 study, sponsored by Suzhou Kintor Pharmaceutical Inc,.
NCT04870606 is a Phase 3 study that has completed, run by Suzhou Kintor Pharmaceutical Inc,. The registered enrollment target is 733 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04870606, a Phase 3 study, has completed, sponsored by Suzhou Kintor Pharmaceutical Inc,.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 733 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of Proxalutamide (GT0918) as a treatment for outpatients COVID-19 subjects.
Primary Outcome
In mITT (administrated at least one dose)，percentage of subjects who do not experience any of the following events due to all causes by Day 28: * Hospitalization for ≥ 24 hours, or * Supplemental oxygen for ≥24 hours in response to SpO2 ≤93%, or * Death
Interventions
- DRUG Placebo
- DRUG Proxalutamide (GT0918)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 733 participants |
| Start Date | 2021-03-05 |
| Est. Completion | 2022-04-06 |
| Phase | Phase 3 |
What the finished NCT04870606 record still lists
NCT04870606 is an interventional study that assigns participants to a tested intervention. The registered 733 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04870606 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04870606 about?
NCT04870606 is a clinical study titled "Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness". The purpose of this study is to assess the efficacy and safety of Proxalutamide (GT0918) as a treatment for outpatients COVID-19 subjects.
What is the current status of trial NCT04870606?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 733 participants. The study started on 2021-03-05. Estimated completion is 2022-04-06.
What interventions are being tested in trial NCT04870606?
The interventions under investigation include: Placebo (DRUG), Proxalutamide (GT0918) (DRUG).
Who is sponsoring clinical trial NCT04870606?
This trial is sponsored by Suzhou Kintor Pharmaceutical Inc,, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04870606's enrollment target sits among peer trials
733 484th of 2000 higher than 1,516 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06216301 · 734 participants · Phase 3
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- NCT07231419 · 734 participants · Phase 3
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
- NCT05947851 · 735 participants · Phase 3
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- NCT05999084 · 735 participants
Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI